Day: June 2, 2025
Novonesis has successfully completed the acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2).
Please read the full announcement in PDF.Attachment2025_Closing_of_the_Feed_Enzyme_Alliance
Dynacor Group Declares June 2025 Dividend
Written by Customer Service on . Posted in Dividend Reports And Estimates.
MONTRÉAL, June 02, 2025 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) announced its monthly dividend payment for June 2025 in the amount of C$0.01333 per common share which will be payable on June 18, 2025, to shareholders of record as of the close of business on June 11, 2025. This dividend represents the sixty-third (63rd) dividend and fifty-third (53rd) monthly dividend payment made to shareholders.
The Corporation’s monthly dividend qualifies as an “eligible dividend” for Canadian income tax purposes.The payment and increase of dividends are at the discretion of the Board and will depend on the Corporation’s financial results, cash requirements, prospects and other factors deemed relevant by the Board.
About Dynacor
Dynacor Group is an industrial ore processing company...
SAIC Announces First Quarter of Fiscal Year 2026 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Revenues of $1.88 billion; approximately 2% revenue growth
Net bookings of $2.4 billion; book-to-bill ratio of 1.3
Net income of $68 million; Adjusted EBITDA(1) of $157 million or 8.4% of revenues
Diluted earnings per share of $1.42; Adjusted diluted earnings per share(1) of $1.92
Cash flows provided by operating activities of $100 million; Free cash flow(1) of $(44) million
Management reaffirms fiscal year 2026 guidanceRESTON, Va., June 02, 2025 (GLOBE NEWSWIRE) — Science Applications International Corporation (NASDAQ: SAIC), a premier Fortune 500 technology integrator driving our nation’s digital transformation across the defense, space, civilian, and intelligence markets, today announced results for the first quarter ended May 2, 2025.
“Our performance in the first quarter reflects the steady progress we are...
GFG Announces Encouraging Phase 1 Drill Results from Pen Gold Project, Ontario
Written by Customer Service on . Posted in Public Companies.
Gold and base metals mineralization intersected at multiple targets; exploration budget increased to support aggressive H2 program
KEY HIGHLIGHTS:Chabot Target: 3.90 grams of gold per tonne (“g/t Au”) over 3.5 metres (“m”), including 9.62 g/t Au over 1 m near surface (PEN-25-100); second zone returned 2.6 g/t Au over 1.3 m with over 1% zinc (1).
Alpha Target (Muskego North Shear Zone): 1.00 g/t Au over 1.0 m (MSK-25-004), confirming the down-dip extension of a 2022 bedrock sample that graded 5.18 g/t Au.
Foxtrot, Bravo, Charlie, and Delta Targets: Multiple zones of stratabound and remobilized sulphide mineralization with elevated gold, copper, and zinc values in structurally and lithologically favorable settings.
Pending results from an additional 5 drill holes at the Aljo Gold Target (“Aljo”) to be released as they become available....
Hyperscale Data Reports $219 Million in Assets at End of Q1 2025, Sells Minority Stake in Private Pharmaceutical Company for $4.65 Million as Part of Company Streamlining
Written by Customer Service on . Posted in Public Companies.
Proceeds to Support Company’s Strategic Focus on Data Center Business
LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) — Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced the sale of its minority equity interest in a privately held pharmaceutical company for gross proceeds of $4.65 million in cash. Hyperscale Data purchased the equity position for $1.5 million in several closings between three and four years ago.
This transaction is consistent with the Company’s ongoing strategy to exit non-core investments and concentrate capital and resources on its primary asset—a 617,000 square foot data center located in Michigan, which is being developed to support high-performance computing (“HPC”) workloads, including artificial intelligence (“AI”) applications.
“As...
Piedmont REIT Signs over 500,000 SF of Leases Second Quarter-to-Date and Raises Full Year Leasing Guidance from 1.4 – 1.6 million SF to 1.8 – 2.0 million SF
Written by Customer Service on . Posted in Public Companies.
YTD Leasing of over 850,000 SF
Atlanta, June 02, 2025 (GLOBE NEWSWIRE) — Piedmont Office Realty Trust, Inc. (“Piedmont” or “the Company”) (NYSE:PDM), an owner of Class A office properties located primarily in the Sunbelt, announced today, that the Company is participating in this week’s Nareit REITWeek Investor Conference in New York City. The Company has completed over 500,000 square feet of leasing thus far in the second quarter, with 350,000 square feet related to new tenants. Approximately 70% of the new tenant leases are for currently vacant space and year-to-date leasing volume now totals over 850,000 square feet. Of note, the Company signed two new, large transactions in excess of 10 years – 93,000 square feet with a global professional services firm specializing in risk, strategy and people at Three Galleria...
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Written by Customer Service on . Posted in Public Companies.
YUTREPIA now available to be prescribed to patients via specialty pharmacies
FDA approved YUTREPIA on May 23, 2025
Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launchMORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23,...
First Atlantic Nickel to Attend Benchmark Mineral Intelligence’s GIGA USA 2025 Conference, Highlighting Atlantic Nickel Project’s Smelter-Free Processing for North America’s Critical Minerals Supply Chain
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) — First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) (“First Atlantic” or the “Company”) is pleased to announce its participation at the Benchmark Mineral Intelligence GIGA USA 2025 conference, taking place June 3-4, 2025, in Washington, DC. The Company will participate in strategic meetings during this critical mineral conference to demonstrate how its Atlantic Nickel Project addresses the growing need for nickel mining that can be completely processed in North America. The Atlantic Nickel Project contains nickel in the form of awaruite, a naturally occurring, sulfur-free, highly magnetic mineral with approximately 75% nickel content. These unique properties enable direct processing through magnetic separation and flotation, eliminating reliance on foreign...
BranchOut Food Inc. Announces Plan to Eliminate Current Liability Notes Payable with $1 Million Warrant Exercise and Extension of Key Financing Agreements
Written by Customer Service on . Posted in Public Companies.
Kaufman Kapital exercises warrant and extends key debt maturities, providing $1 million in support of BranchOut’s financial strategy
BEND, Ore., June 02, 2025 (GLOBE NEWSWIRE) — BranchOut Food Inc. (NASDAQ: BOF), a leading food technology company specializing in its patented GentleDry™ dehydrated snacks and ingredients, announces the execution of a strategic agreement with Kaufman Kapital LLC, resulting in a $1 million cash infusion through the early exercise of existing warrants. The agreement also includes amendments to existing financing terms that strengthen BranchOut’s balance sheet, allow for debt repayment and extend key debt maturities.
Under the terms of the agreement, Kaufman Kapital will exercise in full an existing warrant to purchase 1,000,000 shares of BranchOut’s common stock, providing the Company with $1,000,000...
Xilio Therapeutics Announces Proposed Public Offering
Written by Customer Service on . Posted in Public Companies.
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is commencing an underwritten public offering of pre-funded warrants to purchase shares of common stock accompanied by Series A warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants), Series B warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants) and Series C warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants). All of the securities to be sold in the proposed offering will be offered by Xilio. The proposed offering is subject to market and other conditions,...